Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inogen IncINGN · Entity 2083 | Director | May 10, 2021 | May 12, 2021 |
| Vaxcyte, Inc.PCVX · Entity 1164 | Director | June 15, 2026 | June 16, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inogen Inc
Report date May 10, 2021 · Filed May 12, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 12,775 |
Reported balance
After 2021-05-10 transaction · row 1
1 source rowRow 1 · 2021-05-10 · Grant · Acquired 2,754 · Balance 12,775 F1: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares were acquired pursuant to a restricted stock unit award, which shall vest on the earlier of (i) the one-year anniversary of the date of grant, or (ii) the day prior to the date of the Annual Meeting of the Issuer's stockholders next following the date of grant, in each case, subject to the reporting person continuing to be a service provider through the applicable vesting date.
Vaxcyte, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 19,481 |
Reported balance
After 2026-06-15 transaction · row 1
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 2,265 · Balance 19,481 F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $49.56 · Expires 2036-06-15 | Direct | 11,389 |
Reported balance
After 2026-06-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-15 · Grant · Acquired 11,389 · Balance 11,389 F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs will fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
F2: The shares of Common Stock subject to the option will vest monthly and fully vest on the earlier of June 15, 2027 or the day prior to the next annual meeting of stockholders, subject to acceleration, and subject to the Reporting Person's continuous service through such date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Flexion Therapeutics Inc
Report date November 19, 2021 · Filed November 19, 2021
Section 16 reporting ended · disclosed 2021-11-19. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 1
1 source rowRow 1 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments. F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.85 · Expires 2025-06-16 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-19 · Disposition to issuer · Disposed 9,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.83 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $20.16 · Expires 2027-06-21 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-11-19 · Disposition to issuer · Disposed 12,500 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.88 · Expires 2030-06-09 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
| Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.22 · Expires 2031-06-23 | Direct | 0 |
Reported balance
After 2021-11-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-11-19 · Disposition to issuer · Disposed 7,000 · Balance 0 F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger, dated as of October 11, 2021, by and among Flexion Therapeutics, Inc. ("Issuer"), Pacira BioSciences, Inc. and Oyster Acquisition Company Inc. ("Purchaser") ("Merger Agreement"), on November 19, 2021, Purchaser merged with and into Issuer, with Issuer continuing as the surviving corporation ("Merger"). At the effective time of the Merger, each share of Issuer's common stock was cancelled in exchange for (i) $8.50 per share in cash ("Cash Amount"), plus (ii) one non-transferable contractual contingent value right per share, which represent the right to receive one or more contingent payments of up to $8.00 per share in the aggregate, in cash, upon the achievement of specified milestones on or prior to December 31, 2030 ("CVR Payments"). Pursuant to the Merger Agreement, these shares were tendered and disposed of at the offer acceptance time in exchange for the right to receive (i) the Cash Amount, plus (ii) any CVR Payments.
F2: At the effective time of the Merger, each outstanding restricted stock unit award ("RSU") was accelerated and became fully vested and was cancelled and converted into the right to receive (i) $8.50 per share of Issuer common stock issuable in settlement of such RSU in cash, net of any withholding taxes required to be deducted and withheld by applicable law, plus (ii) any potential CVR Payments.
F3: At the effective time of the Merger, each outstanding option with an exercise price equal to, or greater than, $9.12 was cancelled without any consideration payable (whether in the form of cash or any potential CVR Payments) in respect of such cancelled option.
Satsuma Pharmaceuticals, Inc.
Report date June 08, 2023 · Filed June 08, 2023
Section 16 reporting ended · disclosed 2023-06-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $27.97 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.60 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-06-08 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.46 | Direct | 0 |
Reported balance
After 2023-06-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-06-08 · Disposition to issuer · Disposed 30,000 · Balance 0 F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration. F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Merger Agreement, each vested option to purchase shares of common stock, par value $0.0001 per share (the "Shares") of the Issuer, with an exercise price that is less than the purchase price of $0.91 per share (the "Offer Price"), that is outstanding immediately prior to the date and time at which the Merger became effective (the "Effective Time") will terminate and be cancelled immediately prior to the Effective Time and converted into the right to receive (a) one non-transferable contractual contingent value right and (b) a lump sum cash payment equal in amount to (i) the number of vested Shares underlying such vested option as of immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of $0.91 over the exercise price per Share underlying such vested option, less any required withholding taxes.
F2: Pursuant to the Merger Agreement, each option that was not a vested option to purchase Shares of the Issuer with an exercise price that is less than the Offer Price and was outstanding immediately prior to the Effective Time was terminated and cancelled immediately prior to the Effective Time for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2018 Filed Mar 2, 2018 22:45 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 2,500 | $43.21 | $108,025.00 |
DisclosureSEC source: 0001209191-18-015919 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:07 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $43.21 | $0.00 |
DisclosureSEC source: 0001209191-17-063877 · doc4.xml · derivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,165 Underlying: Common Stock · 2,500 shares Expires 2022-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Subject to reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), 1/12th of the total shares subject to the option vested monthly, beginning with the first month anniversary after the vesting commencement date, but vested fully on the date of the 2016 Annual Meeting of the Issuer's stockholders held after the vesting commencement date. The vesting commencement date for this option was October 14, 2015. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:07 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 500 | $127.28 | $63,640.00 |
DisclosureSEC source: 0001209191-17-063877 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F3 · price: Represents the weighted average share price of an aggregate total of 500 shares sold in the price range of $126.88 to $127.68 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:07 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,000 | $126.18 | $252,358.60 |
DisclosureSEC source: 0001209191-17-063877 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 2,000 shares sold in the price range of $125.78 to $126.72 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 01, 2017 Filed Dec 5, 2017 21:07 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 2,500 | $43.21 | $108,025.00 |
DisclosureSEC source: 0001209191-17-063877 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:20 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 2,500 | $0.00 Strike: $43.21 | $0.00 |
DisclosureSEC source: 0001209191-17-052007 · doc4.xml · derivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,665 Underlying: Common Stock · 2,500 shares Expires 2022-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Subject to reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), 1/12th of the total shares subject to the option vested monthly, beginning with the first month anniversary after the vesting commencement date, but vested fully on the date of the 2016 Annual Meeting of the Issuer's stockholders held after the vesting commencement date. The vesting commencement date for this option was October 14, 2015. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:20 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 2,500 | $97.44 | $243,597.75 |
DisclosureSEC source: 0001209191-17-052007 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 1, 2017. F2 · price: Represents the weighted average share price of an aggregate total of 2,500 shares sold in the price range of $97.16 to $97.82 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 06, 2017 Filed Sep 8, 2017 17:20 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 2,500 | $43.21 | $108,025.00 |
DisclosureSEC source: 0001209191-17-052007 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 22, 2017 Filed Jul 27, 2017 09:38 UTC | Flexion Therapeutics Inc FLXN · Entity 16545 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $20.16 | $0.00 |
DisclosureSEC source: 0001209191-17-046390 · doc4.xml · derivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The stock option vests and becomes exercisable in 12 equal monthly installments following the date of grant. Read SEC document |
| May 30, 2017 Filed May 31, 2017 20:49 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 1,754 | $0.00 Strike: $43.21 | $0.00 |
DisclosureSEC source: 0001209191-17-036477 · doc4.xml · derivative · entry 6 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,165 Underlying: Common Stock · 1,754 shares Expires 2022-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), 1/12th of the total shares subject to the option vested monthly, beginning with the first month anniversary after the vesting commencement date, but vested fully on the date of the 2016 Annual Meeting of the Issuer's stockholders held after the vesting commencement date. The vesting commencement date for this option was October 14, 2015. Read SEC document |
| May 30, 2017 Filed May 31, 2017 20:49 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 1,754 | $88.30 | $154,878.20 |
DisclosureSEC source: 0001209191-17-036477 · doc4.xml · nonDerivative · entry 4 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| May 30, 2017 Filed May 31, 2017 20:49 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 1,754 | $43.21 | $75,790.34 |
DisclosureSEC source: 0001209191-17-036477 · doc4.xml · nonDerivative · entry 3 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,754 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:49 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionStock Option (right to buy) · Derivative | 7,246 | $0.00 Strike: $43.21 | $0.00 |
DisclosureSEC source: 0001209191-17-036477 · doc4.xml · derivative · entry 5 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,919 Underlying: Common Stock · 7,246 shares Expires 2022-10-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Subject to reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), 1/12th of the total shares subject to the option vested monthly, beginning with the first month anniversary after the vesting commencement date, but vested fully on the date of the 2016 Annual Meeting of the Issuer's stockholders held after the vesting commencement date. The vesting commencement date for this option was October 14, 2015. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:49 UTC | Inogen Inc INGN · Entity 2083 | SaleCommon Stock | 7,246 | $88.57 | $641,765.18 |
DisclosureSEC source: 0001209191-17-036477 · doc4.xml · nonDerivative · entry 2 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Represents the weighted average share price of an aggregate total of 7,246 shares sold in the price range of $88.300 to $88.935 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| May 26, 2017 Filed May 31, 2017 20:49 UTC | Inogen Inc INGN · Entity 2083 | Exercise / conversionCommon Stock | 7,246 | $43.21 | $313,099.66 |
DisclosureSEC source: 0001209191-17-036477 · doc4.xml · nonDerivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,246 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 11, 2017 Filed May 12, 2017 17:39 UTC | Inogen Inc INGN · Entity 2083 | GrantStock Option (right to buy) · Derivative | 12,832 | $0.00 Strike: $83.30 | $0.00 |
DisclosureSEC source: 0001209191-17-031810 · doc4.xml · derivative · entry 1 Lukatch Heath · CIK 0001596385 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,832 Underlying: Common Stock · 12,832 shares Expires 2024-05-10 F1 · derivative.exercise_date: Subject to reporting person's continuing to be a Service Provider (as defined in the 2014 Equity Incentive Plan), 1/12th of the total shares subject to the option shall vest monthly, beginning with the first month anniversary after the vesting commencement date, but will vest fully on the date of the next Annual Meeting of the Issuer's stockholders held after the vesting commencement date. The vesting commencement date for this option is May 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.